25 articles with Pear Therapeutics
Pear Therapeutics Announces FDA Submission for Somryst™, a Prescription Digital Therapeutic for the Treatment of Adults with Chronic Insomnia and Depression
Pear Therapeutics announced the filing of a submission to the U.S. Food and Drug Administration seeking marketing authorization for Somryst™, a prescription digital therapeutic intended for use in the treatment of adults with chronic insomnia and depression.
Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced that Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will participate in the Oppenheimer Summit for Emerging Biotechnology being held June 27-28 in Montauk, New York.
Pear Therapeutics Initiates Feasibility Study to Treat Depressive Symptoms in People With Multiple Sclerosis
Novel Prescription Digital Therapeutic Will Be Evaluated for Feasibility and Usability Iterative Design Process Incorporates Extensive Patient and Clinician Feedback
Pear Therapeutics, Inc. announced that Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will present at Oppenheimer’s 29th Annual Healthcare Conference in New York on Tuesday, March 19 at 9:45 a.m. Eastern Time.
Cross-Disciplinary Syndicate Provides Growth Capital to Advance Prescription Digital Therapeutics
Pear Therapeutics, Inc. today announced that Corey McCann, M.D., Ph.D., President and CEO, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9 at 1:30 p.m. Pacific Time.
Pear Therapeutics Announces Initiation of Proof of Concept Study for Prescription Digital Therapeutic in Development for the Treatment of Schizophrenia
Proof of Concept Study Will Evaluate Pear-004 in Combination With Anti-Psychotic Medication Against Standard of Care Treatment Alone
reSET-O™ is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder
Pear Therapeutics Presents New Data on reSET® and reSET-O™ at American Academy of Addiction Psychiatry Annual Meeting and Scientific Symposium
New analysis of randomized clinical trial data for reSET demonstrate two-fold increase in abstinence and treatment retention for patients with Substance Use Disorder; highlight significant dose/response relationship
Digital therapeutics panel discussion at the Evercore ISI HEALTHCONx Conference on Wednesday, November 28 at 6:00 p.m. at the Boston Harbor Hotel.
Sandoz and Pear Therapeutics Announce Launch of reSET® for Treatment of Patients with Substance Use Disorder
reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD)
Pear Therapeutics, Inc. today announced its participation in the BTIG Biotech Conference and the Stifel Healthcare Conference.
Pear Therapeutics, Inc. will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9th at 10:30 a.m. at the InterContinental Boston.
5/30/2018Since 2009 May 30 has been set aside as a day to raise awareness and campaign for an end to multiple sclerosis. The theme this year is focused on the research being conducted to develop a cure for the neurological disease.
Pear Therapeutics, Inc. announced that Corey McCann, M.D., Ph.D., President and CEO, will present at the Jefferies 2018 Healthcare Conference.
The Digital Therapeutics Alliance (DTA) welcomes nine companies to membership
Pear Therapeutics, Inc. today announced a deal with Sandoz, a division of Novartis, to commercialize its two lead products, reSET® and reSET-O™.
3/1/2018Novartis inked a collaboration deal with Pear Therapeutics to develop prescription digital therapeutics for schizophrenia and multiple sclerosis (MS).
Pear Therapeutics announced today that it has entered into a collaboration with Novartis to develop novel prescription digital therapeutics for schizophrenia and multiple sclerosis (MS).
The funds raised will be used to further commercialize reSET and its pipeline and platform.